» Articles » PMID: 35406585

Genetic Clonality As the Hallmark Driving Evolution of Non-Small Cell Lung Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Apr 12
PMID 35406585
Authors
Affiliations
Soon will be listed here.
Abstract

Data indicate that many driver alterations from the primary tumor of non-small cell lung cancer (NSCLC) are predominantly shared across all metastases; however, disseminating cells may also acquire a new genetic landscape across their journey. By comparing the constituent subclonal mutations between pairs of primary and metastatic samples, it is possible to derive the ancestral relationships between tumor clones, rather than between tumor samples. Current treatment strategies mostly rely on the theory that metastases are genetically similar to the primary lesions from which they arise. However, intratumor heterogeneity (ITH) affects accurate diagnosis and treatment decisions and it is considered the main hallmark of anticancer therapy failure. Understanding the genetic changes that drive the metastatic process is critical for improving the treatment strategies of this deadly condition. Application of next generation sequencing (NGS) techniques has already created knowledge about tumorigenesis and cancer evolution; however, further NGS implementation may also allow to reconstruct phylogenetic clonal lineages and clonal expansion. In this review, we discuss how the clonality of genetic alterations influence the seeding of primary and metastatic lesions of NSCLC. We highlight that wide genetic analyses may reveal the phylogenetic trajectories of NSCLC evolution, and may pave the way to better management of follow-up and treatment.

Citing Articles

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.

Lui K, Cheung K, Ng W, Wang Y, Au D, Cho W Int J Mol Sci. 2024; 25(22).

PMID: 39596025 PMC: 11594099. DOI: 10.3390/ijms252211954.


ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance.

Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V JTO Clin Res Rep. 2024; 5(9):100703.

PMID: 39309618 PMC: 11416292. DOI: 10.1016/j.jtocrr.2024.100703.


Using Copy Number Variation Data and Neural Networks to Predict Cancer Metastasis Origin Achieves High Area under the Curve Value with a Trade-Off in Precision.

Mickael M, Kubick N, Atanasov A, Martinek P, Horbanczuk J, Floretes N Curr Issues Mol Biol. 2024; 46(8):8301-8319.

PMID: 39194707 PMC: 11352492. DOI: 10.3390/cimb46080490.


Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals Mutations to Be Associated With Longer Overall Survival.

De B, Farooqi A, Mitchell K, Ludmir E, Lewis J, Rinsurongkawong W JCO Precis Oncol. 2023; 7:e2200540.

PMID: 36716413 PMC: 9928880. DOI: 10.1200/PO.22.00540.


Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases.

Nicos M, Harbers L, Patrucco E, Kramer-Drauberg M, Zhang X, Voena C JTO Clin Res Rep. 2022; 3(12):100435.

PMID: 36561283 PMC: 9763853. DOI: 10.1016/j.jtocrr.2022.100435.


References
1.
Priestley P, Baber J, Lolkema M, Steeghs N, de Bruijn E, Shale C . Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019; 575(7781):210-216. PMC: 6872491. DOI: 10.1038/s41586-019-1689-y. View

2.
Testa U, Castelli G, Pelosi E . Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel). 2018; 10(8). PMC: 6116004. DOI: 10.3390/cancers10080248. View

3.
Brown M, Assen F, Leithner A, Abe J, Schachner H, Asfour G . Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science. 2018; 359(6382):1408-1411. DOI: 10.1126/science.aal3662. View

4.
Birkbak N, McGranahan N . Cancer Genome Evolutionary Trajectories in Metastasis. Cancer Cell. 2020; 37(1):8-19. DOI: 10.1016/j.ccell.2019.12.004. View

5.
Vu T, Jin L, Datta P . Effect of Cigarette Smoking on Epithelial to Mesenchymal Transition (EMT) in Lung Cancer. J Clin Med. 2016; 5(4). PMC: 4850467. DOI: 10.3390/jcm5040044. View